Related Experiment Video

Updated: Aug 15, 2026

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses
06:13

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses

Published on: November 24, 2014

Selectively replicating oncolytic adenoviruses as cancer therapeutics

De-Chao Yu1, Peter Working, Dale Ando

  • 1Cell Genesys Inc, Foster City, CA 94404, USA.

Current Opinion in Molecular Therapeutics
|November 19, 2002
PubMed

Insights

Virotherapy using oncolytic adenoviruses shows promise for cancer treatment, demonstrating antitumor activity and safety. Future research will focus on enhancing efficacy and combining them with traditional therapies.

Area of Science:

  • Oncology
  • Virology
  • Gene Therapy

Background:

  • Virotherapy has resurged as a promising cancer treatment modality.
  • Transcriptionally regulated adenovirus variants selectively target and destroy tumor cells.

Purpose of the Study:

  • To review the progress and future directions of oncolytic adenoviruses in cancer therapy.
  • To highlight the potential of these viruses in combination with conventional treatments.

Main Methods:

  • Review of existing research on oncolytic adenoviruses.
  • Analysis of clinical data for safety and efficacy of CG-7060 and CG-7870.
  • Exploration of synergistic effects with chemotherapy and radiotherapy.

Main Results:

  • Oncolytic adenoviruses demonstrate good safety profiles and significant antitumor activity.
  • Synergistic antitumor effects observed when combined with chemotherapy or radiotherapy.

Conclusions:

  • First-generation oncolytic adenoviruses show clinical utility.
  • Future development requires improving antitumor efficacy, modulating immune responses, and optimizing combination therapies.

More Related Videos

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...